白质超强度和阿尔茨海默氏病连续体内的多种病理之间的时空相互作用
Li Liang1,2, Wei Liu1, Youping Zhong1
1Department of Electronic & Information Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen, China.
概括
阿尔茨海默病 (AD) 研究显示,粉样β (Aβ) 积累驱动特定大脑网络中的白质超强度 (WMHs). WMHs还与关键白质道中的微观结构损伤相关.
科学领域:
- 神经成像是一种神经成像.
- 神经病理学神经病理学
- 网络神经科学 网络神经科学
背景情况:
- 大脑网络中的阿尔茨海默病 (AD) 和白质强度过高 (WMHs) 相互作用尚未完全理解.
- 澄清这些关系对于理解AD进展至关重要.
研究的目的:
- 研究AD病理和WMHs之间的动态,多尺度的相互作用.
- 模拟粉样β (Aβ),WMHs和白质微观结构变化的相互作用.
主要方法:
- 利用了来自阿尔茨海默病神经成像计划 (ADNI) 数据库的数据.
- 模拟区域WMH,Aβ积累和微观结构变化,使用时间演变图表.
- 应用格兰杰因果分析对伪时间主体序列,以确定因果关系.
主要成果:
- 在86%的序列中,Aβ积累被确定为下纵向 (ILF) 结构网络中WMHs的格兰杰原因.
- 显著相关的WMHs与微观结构变化 (减少分数异构) 在ILF,下面的前额皮和环.
结论:
- 这些发现揭示了WMH和AD病理之间的复杂,时间依赖的相互作用.
- 提供了关于大脑小血管疾病和AD之间的关系的见解.
更多相关视频
15:263D Modeling of the Lateral Ventricles and Histological Characterization of Periventricular Tissue in Humans and Mouse
Published on: May 19, 2015
14.0K
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
13.9K
相关概念视频
01:26Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128